Company Overview and News

 
Rockwell debuts in Laguna

2018-10-02 business.inquirer.net
Upscale property developer Rockwell Land Corp. is debuting into Laguna’s robust property market with a joint venture with the Yulo family to develop a 63-hectare mixed-use project in Canlubang.
ROCK PSKXF PHSXY PSE

7
‘Servathon’ dedicated to children of Marawi

2018-09-30 newsinfo.inquirer.net
Employees and officials of at least 28 companies in Metro Manila, including the Inquirer, did just that on Saturday.
WFC WFCNP CIC ICT ROCK NTRSP FEU ICTEF NTRS IM

 
Developers report mixed Q2 results

2018-08-20 bworldonline
SEVERAL PROPERTY companies reported mixed performances in the second quarter of 2018, with Rockwell Land Corp. posting strong real estate sales, while others saw a drop in revenues.
ALHI ROCK

 
Property firms post mixed second-quarter results

2018-08-20 bworldonline
Property companies reported mixed performances in the second quarter of 2018, depending on the real estate sales and rental income each firm posted for the period.
ALHI ROCK

 
Before buying that serum, test it at this ‘open spa’

2018-08-02 lifestyle.inquirer.net
Rustan’s April Marquez, SSI Group president AntonHuang, Clarins’ Marine Lux, Rustan’s president Donnie Tantoco and Rockwell Land’s Lisa Gomez open the new Clarins boutique in Power Plant Mall. —ALEXIS CORPUZ
ROCK SSI

 
Rockwell seeks to boost land bank

2018-05-30 bworldonline
ROCKWELL LAND Corp. is keeping its capital expenditures steady this year, but is ramping up spending for land acquisitions to grow its land bank until 2019.
ROCK

 
Property companies deliver mixed results in Q1

2018-05-17 bworldonline
SOME property developers in the country reported mixed results for the first quarter of 2018, amid sustained demand for residential projects.
ROCK RLC RBLAY

5
Condo sales lift Rockwell Land profits

2018-04-17 bworldonline
ROCKWELL Land Corp. posted double-digit profit growth last year, following improved condominium sales and more project completions.
ROCK PSKXF PHSXY PSE

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to PSE:ROCK / Rockwell Land Corporation on message board site Silicon Investor.

Slumdogu0027s Rockpile Slumdogu0027s Rockpile Slumdogu0027s Rockpile Rocky Mountain High Brands Rocky Mountain High Brands Rocky Mountain High Brands
Rockwell on the prowl? Rockwell on the prowl? Rockwell on the prowl? Rocky Mountain Ayre, Inc. Rocky Mountain Ayre, Inc. Rocky Mountain Ayre, Inc.
IRO.V - Inter-Rock Minerals Inc.(Dolomite Supplier) IRO.V - Inter-Rock Minerals Inc.(Dolomite Supplier) IRO.V - Inter-Rock Minerals Inc.(Dolomite Supplier) Rockwell Medical Technologies (RMTI, RMTIW) Rockwell Medical Technologies (RMTI, RMTIW) Rockwell Medical Technologies (RMTI, RMTIW)
Rocky Mountain Intu0027l (OTC:RMIL former OTC:OVIS) Rocky Mountain Intu0027l (OTC:RMIL former OTC:OVIS) Rocky Mountain Intu0027l (OTC:RMIL former OTC:OVIS) Canadian Rocket Redu0027s Picks Canadian Rocket Redu0027s Picks Canadian Rocket Redu0027s Picks
Isaac Brock Social Site - Liberty and Justice for all United Isaac Brock Social Site - Liberty and Justice for all United Isaac Brock Social Site - Liberty and Justice for all United Rocky Brands RCKY Rocky Brands RCKY Rocky Brands RCKY